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A 52 year-old man with a past medical history of an
isolated seizure presented to the Veterans Affairs hospital
complaining of weakness which was most prominent in
the face and upper extremities. About 6 months prior to
this admission he developed intermittent episodes of
weakness when chewing and swallowing. He would often
have to use his hands to close his jaw when eating or
talking. He noticed that his voice had developed a nasal
quality but he did not have slurred speech. He denied
drooling, ptosis, cramping or muscle twitches. He was
seen 6 months ago at another VA hospital where a
neurologic workup was done. This included a cranial
nerve EMG positive for denervation of cranial nerves, R
arm and T- and L-spine. MRI and CT scans could not
be done because the patient aspirated when supine. He
was given a presumptive diagnosis of motor neuron
disease, specifically bulbar ALS. At that time he was told
he would need a PEG-feeding tube placed due to
significant weight loss. The patient refused the feeding
tube and did not follow up until again until 6 months
later when the symptoms had worsened. 
The patient’s past medical history included an isolated
seizure about 8 years ago. He had been taking phenytoin
but it was discontinued several months ago after periodic
negative EEG’s. His family history was significant for a
transient ischemic attack in his mother. There was no
other family history of neurologic or systemic disorder.
He had a 35 pack-year history of tobacco smoking. He
also occasionally smoked marijuana. He quit drinking
beer about a year ago and said he never drank heavily.
The patient had a remote history of intravenous heroin
use and was eager to undergo testing for HIV. He was
employed as a roofer but quit recently because he was
having to use his hands to hold his head up while
working. There were no known occupational exposure
to asbestos or chemicals.
The patient’s heart, lung and abdominal exams were
normal. On neurologic and musculoskeletal exam, the
cranial nerves were intact. He had no tongue or facial
fasciculations but did have bilateral temporal and
masseter wasting. He had full strength throughout, but
had slightly diminished vibratory sensation of the feet.
There were no peripheral fasciculations or wasting. Deep
tendon reflexes were +2/4 throughout. Cerebellar and
Romberg exams were normal and there was no Babinski
sign. The diagnsosis of ALS was questioned and the
patient underwent further neurologic workup.
His metabolic panel, complete blood count and thyroid
function tests were within normal limits, as were the B12
and folate levels. His HIV test was negative, while
Hepatitis C antibody was positive with an undetectable
viral load. Albumin was low at 2.7. The patient was able
to lie supine for a brain MRI. The MRI and a chest
radiograph were unremarkable. He underwent a
videofluoroscopic swallowing study which revealed
moderate oropharyngeal dysphagia with increased
vallecular residue and impaired elevation of the larynx.
There was no esophageal dysfunction. Pulmonary
function tests showed a decrease in forced inspiratory
flow @ 39%.
He had an acetylcholine receptor antibody level was 3.62
nmol/L (normal up to 0.4). His SPEP was near-normal
with a slight polyclonal elevation (IgM and IgG). The
IgA was slightly low. A noncontrast chest CT showed a
lobulated mass in the anterior mediastinum measuring 5
x 3.8 cm, extending from the sternum and abutting the
SVC and aorta. (see Figure 1) The mass contained few
calcifications. A lesion was seen in the anterior
mediastinum just to the right of the sternum. It was
pleural-based and measured 2 x 0.8cm. Another pleural-
based lesion was seen in the right posterolateral chest.
Finally, there were several smaller, nodular soft tissue
lesions of similar density within the right lung. A CT-
guided biopsy was done on the anterior mediastinal
lesion. It revealed a WHO Type B3 epithelial thymoma.
(See Table 2).
While reviewing the CT scan for a possible substernal
thymectomy, surgery requested that interventional
radiology biopsy of one of the pleural lesions. The biopsy
of the pleural-based posterolateral chest lesion (see Figure
2) was also consistent with epithelial thymoma. CT scans
of the neck, abdomen and pelvis showed no evidence of
other metastases. Since thymectomy would not be
curative for a metastatic lesion the patient was referred
to oncology where he was started on chemotherapy with
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cisplatin, cyclophosphamide and adriamycin. He was
also started on pyridostigmine for control of the
myasthenia gravis. Chemotherapy was uncomplicated
but a few weeks later the patient was admitted for
community-acquired pneumonia and diarrhea. He was
started on the appropriate antibiotic regimen and his
pyridostigmine was withheld for diarrhea. During this
acute illness the patient was so profoundly weak he had
to constantly lean forward in bed to allow saliva to drain.
Just as the decision was made to move the patient to an
intensive care unit and electively intubate him for airway
protection, his condition began to improve. He was once
again able to swallow and within 3 days he had regained
almost full strength. At this point he was a few weeks out
from chemotherapy and a follow-up chest CT showed a
marked decrease in the size of the patient’s mediastinal
mass (and pleural/lung masses). 
Discussion
This patient was initially diagnosed with motor neuron
disease, specifically bulbar amyotrophic lateral sclerosis.
It is difficult to tell why the diagnosis of myasthenia
gravis was not made initially. The patient had less than
optimal follow up and the clinical picture was further
complicated because the patient’s report of symptom
onset at the time of a neck injury several years before.
The physicians who first saw him must have wondered
whether his fall from a ladder was a cause or result of his
symptoms. Furthermore, the patient was taking his
anticonvulsant medication eratically and his desire to
taper off his anticonvulsant was a priority. 
Thymomas are the most common primary anterior
mediastinal tumor and account for 15-20% of all
mediastinal masses1. Thymomas are derived from
epithelial thymus cells with varying degrees of atypia,
along with normal lymphocytes. These tumors should
be distinguished from thymomas involving lymphomas,
germ cell tumors, carcinoid tumors a small cell cancer.
Thymomas are associated with many paraneoplastice
syndromes, the most common of which is myasthenia
gravis, which is seen in about 30% of patients with
thymomas. Other paraneoplastic syndromes include
pure red cell aplasia, acquired hypogamaglobulinemia
and connective tissue disorders such as Sjogren’s
syndrome, myocarditis, dermatomyositis, SLE and
rheumatoid arthritis.
About 15% of myasthenia gravis patients have
thymomas. This has resulted in widespread screening for
thymoma in MG patients.  In other cases, thymomas are
usually picked up by routine CXR or when patients
present with symptoms secondary to mass effects, such
as coughing, shortness of breath or chest pain. 
There are several classification systems for thymomas.
The Lattes/Bernatz, Rosai/Levine and Muller-Mermelink
are based on microscopic appearance alone while the
more commonly used Masaoka system is based on degree
of invasion. A fourth classification system proposed by
the World Health Organization was used with this
patient.  There is controversy regarding the most useful
classification system in terms of predicting survival.
Several of the studies used to develop these classification
systems involved small numbers of patients. From a
practical standpoint, the degree of invasiveness.
While it has often been reported that myasthenia gravis
portends a worse prognosis in patients with thymoma, a
more recent study patients with thymomas and
myasthenia gravis appear to have a significantly better
overall prognosis that those without myasthenia
symptoms. It would appear that patients with
myasthenia symptoms present earlier in the course of
disease and the thymoma was caught at an earlier stage.
However, one series has shown that this is not the case.
Also, patients with myasthenia gravis are more likely to
follow-up with their doctors and get better care for all of
their medical problems. It has been shown that most
patients with thymomas (invasive or noninvasive) tend
to die of medical problems other than the thymoma.  A
third possible explanation was myasthenia patients seem
to do better may be because some of them get treated
with steroids, which can lead to involution of thymomas.
Interestingly, while myasthenia appears to be a good
independent predictor of survival, resection or “cure” of
thymomas typically does not affect the myasthenia
symptoms. The most significant independent predictor
of survival is surgical resectability at initial presentation.
Other independent risk factors for improved survival are
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absence of advanced pathologic stage (per the
Lattes/Bernatz classification) and age < 57 yrs.1
Treatment for thymoma is generally involves surgical
resection, with a recurrence rate of about 2% for
encapsulated tumors and about 20-40% for invasive
lesions. Preoperative radiation therapy does not generally
improve survival, but adjuvant postoperative therapy is
considered the standard of care for completely or
incompletely resected stage III or stage IV thymomas. For
metastatic thymoma, this is generally not possible
chemotherapy should be considered. Candidates for
chemotherapy include about 1/3 of patients with invasive
thymoma and all patients with stage IV disease. The usual
regimen is cisplatin, doxorubicin and cyclophosphamide
(PAC). Chemotherapy is followed by radiation and in one
study this resulted in a 52% five year survival rate.2,3
In summary, thymoma should be considered in any
patient with myasthenia gravis. The most important
predictor of survival is surgical respectability at initial
presentation. Finally, the presence myasthenia gravis is a
predictor of improved survival in thymoma.  
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Figure 1. Noncontrast chest CT showing mass 
in anterior mediastinum
Table 1. Masaoka Classification
Stage Extent of disease 
I Totally encapsulated
II Capsular invasion and/or invasion 
into surrounding fat or pleura
III Invasion into organs 
(pericardium, lung, great vessels)
Iva Pleural or pericardial implants
IVb Hematogenous metastases
Table 2. WHO Classification
Histological Types Characterization 
WHO Classification  This system is based upon the 
ofThymic Epithelial  morphology of the epithelial cells 
Tumors(1999) as well as the lymphocyte to 
epithelial cell ratio
Type A Homogeneous population of neoplastic
epithelial cells having spindle/oval shape,
lacking nuclear atypia, and accompanied by
few or no non-neoplastic lymphocytes 
Type AB Foci having the features of type A admixed
with foci rich in lymphocytes; the segregation
of the two patterns can be sharp and distinct
Type B1 Resembles the normal functional thymus by
combininglarge expanses with an appearance
practically indistinguishable from normal
thymic cortex with areas resembling thymic
medulla
Type B2 Neoplastic epithelial component appears as
scattered plump cells with vesicular nuclei
and distinct nucleoli among a heavy
population of lymphocytes; perivascular
spaces are common
Type B3 Predominately composed of epithelial cells
having round or polygonal shape and
exhibiting mild atypia admixed with a minor
component of lymphocytes, foci of 
squamous metaplasia and perivascular spaces
are common
Type C Thymic carcinoma
Variants
Figure 2. CT-guided biopsy of pleural-based mass
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